This Phase 3 study, comprising a double-blind, placebo-controlled treatment period of up to 48 weeks, will assess the efficacy and safety of seralutinib versus placebo when added to background PAH disease-specific medication in adult PAH subjects who are WHO FC II or III. The primary objective of the study is to assess the efficacy of seralutinib relative to placebo with a primary endpoint of change from baseline to Week 24 in 6MWD.

This is a Phase 2, double-blind, randomized, placebo-controlled study of KER-012 (study drug) compared to Placebo in adult participants with a primary diagnosis of Pulmonary Arterial Hypertension (PAH) on stable background PAH therapy. About 90 participants, in approximately 60 study centers worldwide, will take part in this study. Participation in this study may last up to 2 years and the study has a Screening period, Treatment period, Extension period, and Follow-up period.

This trial is for patients with bronchiectasis who completed the Boehringer Ingelheim 1397-0012 Airleaf parent study. This is a continuation of the Airleaf study and is meant to assess the long-term safety, effectiveness, and tolerability of the study drug (BI 1291583). Approximately 220 patients will be enrolled into the study and will be randomized into either 1 milligram, 2.5 milligram, or 5 milligram study drug or placebo. Patients will be treated for approximately 1 year, while study staff monitor the number of patient pulmonary exacerbations.

The study will test OATD-01, an experimental medicine, for the first time in patients with pulmonary sarcoidosis (swollen tissue in the lungs). The study goal is to evaluate OATD-01 in the reduction of inflammation and assessing OATD-01 safety.

Everyone who participates in this study will receive OATD-01 or matching placebo (inactive mock tablet). Subjects will be randomly assigned to receive either OATD-01 or placebo for 12 weeks.

The study will run in several hospitals or outpatient clinics, in different countries in Europe and in the USA. In this study, there will be about 98 study subjects in total.

For all patients whether taking OATD-01 or matching placebo, there will be a screening period, a treatment period which will commence after randomization has taken place and will last for 12 weeks and then a follow up visit approximately 4 weeks post last dose of OATD-01.

The total duration of the study is 18 weeks.

This is a double-blind, randomized, placebo-controlled study of CMTX-101 in pwCF who are 18 years of age or older and chronically infected with P. aeruginosa. This study will evaluate the safety and tolerability, PK, immunogenicity, reduction of pulmonary P. aeruginosa burden, and exploratory endpoints of CMTX-101 in up to 41 participants. This study has 2 parts.

This is a research study involving an investigational drug called RT234. RT234 is being developed to treat pulmonary arterial hypertension (PAH). Eligible subjects must have a confirmed diagnosis of PAH and be on stable disease-specific PAH background therapy. The purpose of this study is to collect more information about the ability of RT234 to improve exercise capacity and safety of RT234 for the treatment of pulmonary arterial hypertension. The total duration of participation in the study, including screening, will be up to 4 study visits and a follow-up telephone call, over a period of up to 14 weeks. Up to 60 subjects will take part in this study.

Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861, the study drug, in subjects who have World Health Organization (WHO) Group 1 & 3 Pulmonary Hypertension. The purpose of this research study is to evaluate the long-term safety and tolerability of LIQ861 in patients with WHO Group 3 Pulmonary Hypertension associated with interstitial lung disease (PH-ILD). The investigational form of Treprostinil in this study is called LIQ861, it is delivered to your lungs using a hand-held device called a dry powder inhaler (DPI). Dose levels may be adjusted by the Study Doctor between 26.5 micrograms to 318 micrograms based on your PH-ILD symptoms. The study will include approximately 60 subjects and participation will last 52 weeks.

This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. This study will be conducted in approximately 20 centers globally, in subjects with IPF. Participation will last for about 18 weeks and include about 12 study clinic visits with the Study Doctor and/or study staff. This study will take place over approximately a year. The study will investigate a single dose level of GRI-0621 of 4.5mg compared with placebo, following once daily oral administration for 12 weeks. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. The study consists of a Screening Period, a Treatment Period and a Safety Follow-Up Period. The Screening Period will be conducted within 4 weeks prior to randomization, and is comprised of at least two separate in-clinic visits to assess eligibility.
Concurrently, a BAL Sub-Study will be conducted, for up to 12 eligible subjects (across various centers). The objective of the Sub-Study is to examine the role of NKT cells in fibrotic lung disease.

Nontuberculous mycobacteria (NTM) cause a chronic pulmonary infection associated with cough, fatigue, and shortness of breath. Our primary objectives are to better understand the trajectory of patient-reported outcomes (PROs), e.g.
respiratory symptoms and health-related quality of life (HRQoL), across the entire disease course and measure toxicity and tolerability using patient-reported symptomatic adverse events in treated patients with nontuberculous mycobacterial pulmonary disease (NTM-PD).

This is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 versus placebo on top of standard of care in subjects with Progressive Pulmonary Fibrosis (PPF) over 52 weeks. Subjects will participate in the study for up to 58 weeks, inclusive of a Screening Period of up to 4 weeks, a 52-week Treatment Period, and a 2-week Follow-up Period that includes a Follow-up telephone call (TC) 2 weeks post final dose. Up to 300 eligible subjects will be randomized in a 2:1:2 ratio to 1 of 3 treatment arms: AP01 100 mg twice daily (BID), AP01 50 mg BID, or placebo BID (8 mL; two 4 mL blow-fill-seal [BFS] ampoules BID).